Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tables, listings and figures in a clinical study report - quality or quantity?

Journal of biopharmaceutical statistics·2025
Same author

Consistency-Based Approach to Adjust for Multiplicity in Confirmatory Subgroup Analysis.

Statistics in medicine·2025
Same author

Response to Comment on "Emerging insights and commentaries - MMRM vs LOCF by Naitee Ting".

Journal of biopharmaceutical statistics·2023
Same author

Emerging insights and commentaries - MMRM vs LOCF.

Journal of biopharmaceutical statistics·2023
Same author

How to select the initial dose for a pediatric study?

Journal of biopharmaceutical statistics·2022
Same author

The potent and selective RIPK2 inhibitor BI 706039 improves intestinal inflammation in the TRUC mouse model of inflammatory bowel disease.

American journal of physiology. Gastrointestinal and liver physiology·2021

Related Experiment Video

Updated: Dec 26, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

1.1K

Statistical Interactions in a Clinical Trial.

Naitee Ting1

  • 11 Boehringer-Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.

Therapeutic Innovation & Regulatory Science
|May 2, 2018
PubMed
Summary
This summary is machine-generated.

New statisticians often test statistical interactions, but estimation is crucial in drug development. This paper clarifies the difference between testing and estimation, emphasizing why interactions are estimated, not tested, in clinical trials per ICH E-9 guidelines.

Keywords:
analysis of covarianceconfirm and exploremultiregional clinical trialstatistical interactionsubgroup analysis

More Related Videos

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.5K
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.1K

Related Experiment Videos

Last Updated: Dec 26, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

1.1K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.5K
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.1K

Area of Science:

  • Biostatistics
  • Clinical Pharmacology
  • Pharmaceutical Development

Background:

  • Industry statisticians frequently default to testing statistical interactions.
  • Real-world applications, particularly in drug development, necessitate the estimation of interactions.
  • A common misconception exists regarding the role of statistical interactions in clinical trials.

Purpose of the Study:

  • To articulate the critical distinction between hypothesis testing and estimation of statistical interactions.
  • To discuss the appropriate application of statistical interactions within clinical development programs.
  • To clarify the rationale behind the International Council for Harmonisation E-9 guideline regarding treatment by subgroup interactions.

Main Methods:

  • Conceptual clarification of hypothesis testing versus estimation.
  • Review of statistical interaction principles in the context of clinical development.
  • Analysis of the ICH E-9 guideline concerning primary statistical analysis models.

Main Results:

  • Hypothesis testing is generally inappropriate for statistical interactions in clinical development.
  • Estimation of interactions is the preferred approach for understanding treatment effects in subgroups.
  • The ICH E-9 guideline advises against including treatment by subgroup interactions in primary analyses due to potential for misleading results.

Conclusions:

  • The focus in clinical development should be on estimating, not testing, statistical interactions.
  • Understanding the distinction between testing and estimation is vital for accurate interpretation of clinical trial data.
  • Adherence to ICH E-9 recommendations ensures robust and reliable drug development processes.